Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedKey initiatives
01Adopt a business strategy centered on MDL-101 as the lead program
02Prioritize research and development in neuromuscular diseases, including MDL-201, where the Company’s know-how can be transferred.
03For central nervous system diseases, resume development subject to determining a delivery method and securing the necessary resources. Research will continue.
04Focus on mechanisms that can be addressed only through epigenome editing
05Focus on disease groups where the characteristics of gene therapy can be utilized
06Target diseases originating in organs for which delivery has been established or is expected to be established in the future
07Maintain and strengthen the biological foundation
08Refine development activities toward clinical transition
09Clear next steps
Plan assumptionsCurrent economic, regulatory, market and other conditions, ¥110 per $1 as the conversion assumption for the global gene therapy sales forecast (fiscal years 2019–2024)
Size of the Target MarketSubject LAMA2-CMD / Market Size More than $500M / Source No source is specified for the market size. The source for prevalence is “Estimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases” (2023)., Subject Global gene therapy sales forecast / Market Size $14.9 billion (2024) [¥1.6397 trillion] / Growth rate CAGR 185.7% / Source Evaluate Ltd. (data as of August 2019)
Risks identified by the company
Various risks and uncertainties
Economic, regulatory, market and other conditions
Reason for revision or withdrawal
Additional analyses to increase confidence in the transition to the clinical stage, refinement of development parameters, maximizing the probability of success through data-driven decision-making, and ensuring alignment with regulatory authorities. The aim is to maximize the long-term probability of clinical success by prioritizing the optimization of biological and clinical readiness.
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential: Revised Edition at the End of Fiscal 2025 |
| Progress against the plan | Partially revised |
| Plan assumptions | Current economic, regulatory, market and other conditions, ¥110 per $1 as the conversion assumption for the global gene therapy sales forecast (fiscal years 2019–2024) |
| Key initiatives | Adopt a business strategy centered on MDL-101 as the lead program, Prioritize research and development in neuromuscular diseases, including MDL-201, where the Company’s know-how can be transferred., For central nervous system diseases, resume development subject to determining a delivery method and securing the necessary resources. Research will continue., Focus on mechanisms that can be addressed only through epigenome editing, Focus on disease groups where the characteristics of gene therapy can be utilized, Target diseases originating in organs for which delivery has been established or is expected to be established in the future, Maintain and strengthen the biological foundation, Refine development activities toward clinical transition, Clear next steps |
| Reason for revision or withdrawal | Additional analyses to increase confidence in the transition to the clinical stage, refinement of development parameters, maximizing the probability of success through data-driven decision-making, and ensuring alignment with regulatory authorities. The aim is to maximize the long-term probability of clinical success by prioritizing the optimization of biological and clinical readiness. |
| Size of the Target Market | Subject LAMA2-CMD / Market Size More than $500M / Source No source is specified for the market size. The source for prevalence is “Estimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases” (2023)., Subject Global gene therapy sales forecast / Market Size $14.9 billion (2024) [¥1.6397 trillion] / Growth rate CAGR 185.7% / Source Evaluate Ltd. (data as of August 2019) |
| Risks identified | Various risks and uncertainties, Economic, regulatory, market and other conditions |
| Publication date | 25 March 2026 |
Items this document does not state (17)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The aim is to maximize the long-term probability of clinical success by conducting additional analyses and refining development parameters to increase confidence in the transition to the clinical stage, while prioritizing the optimization of biological and clinical readiness.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.